Cargando…

Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis

BACKGROUND: Overall Disability Response Score (ODRS) is a composite endpoint including Expanded Disability Status Scale, Timed 25-foot Walk, and 9-Hole Peg Test, designed to quantify both disability improvement and worsening in multiple sclerosis (MS). OBJECTIVE: To assess the sensitivity and clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Ih, Kappos, Ludwig, Giovannoni, Gavin, Calabresi, Peter A, Sandrock, Alfred, Cheng, Wenting, Xiao, Shan, Riester, Katherine, Belachew, Shibeshih, Deykin, Aaron, Zhu, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732786/ https://www.ncbi.nlm.nih.gov/pubmed/36131595 http://dx.doi.org/10.1177/13524585221114997

Ejemplares similares

Recurrent disability progression endpoints in multiple sclerosis clinical trials
por: Bühler, Alexandra, et al.
Publicado: (2022)

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
por: Kappos, Ludwig, et al.
Publicado: (2020)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017)

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)
por: Wiendl, Heinz, et al.
Publicado: (2016)

Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
por: Beynon, Vanessa, et al.
Publicado: (2022)

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Measuring treatment response to advance precision medicine for multiple sclerosis
por: Calabresi, Peter A., et al.
Publicado: (2021)

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
por: Wolinsky, Jerry S., et al.
Publicado: (2018)

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
por: Miller, David H., et al.
Publicado: (2018)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients
por: Roura, Eloy, et al.
Publicado: (2021)

Deep gray matter volume loss drives disability worsening in multiple sclerosis
por: Eshaghi, Arman, et al.
Publicado: (2018)

Gut microbiome composition is associated with long-term disability worsening in multiple sclerosis
por: Devolder, Lindsay, et al.
Publicado: (2023)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study
por: Binzer, Stefanie, et al.
Publicado: (2019)

Predictors of disability worsening in clinically isolated syndrome
por: Jokubaitis, Vilija G, et al.
Publicado: (2015)

Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab
por: Wang, Y. C., et al.
Publicado: (2011)

Heart rate variability is differentially altered in multiple sclerosis: implications for acute, worsening and progressive disability
por: Studer, Valeria, et al.
Publicado: (2017)

Does a modifiable risk factor score predict disability worsening in people with multiple sclerosis?
por: Marck, Claudia H, et al.
Publicado: (2019)

A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2021)

Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
por: Colato, Elisa, et al.
Publicado: (2021)

Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis
por: Peeters, Gertjan, et al.
Publicado: (2023)

Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis
por: Weier, Katrin, et al.
Publicado: (2014)

The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis
por: Shribman, Samuel, et al.
Publicado: (2017)

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2023)

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Ensemble machine learning identifies genetic loci associated with future worsening of disability in people with multiple sclerosis
por: Fuh-Ngwa, Valery, et al.
Publicado: (2022)

Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients
por: Parmar, Katrin, et al.
Publicado: (2021)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide
por: Sprenger, Till, et al.
Publicado: (2019)

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
por: Elliott, Colm, et al.
Publicado: (2019)

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
por: Fox, Edward J, et al.
Publicado: (2018)

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2021)

Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients
por: Chen, Xinjie, et al.
Publicado: (2023)

Revisiting Brain Atrophy and Its Relationship to Disability in Multiple Sclerosis
por: Shiee, Navid, et al.
Publicado: (2012)

A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
por: Salter, Amber, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g2vaupi8bnb2pvju15esfpvht9